Jump to main content
Jump to site search

Issue 43, 2007
Previous Article Next Article

Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

Author affiliations

Abstract

Copper(II)-diacetyl-bis(N4-methylthiosemicarbazone), Cu–ATSM, labeled with a positron emitting isotope of copper (60Cu, 61Cu, 62Cu or 64Cu) has been shown, in vitro and in vivo, to be selective for hypoxic tissue. In silico studies have explored the mechanism of its hypoxia selectivity, and clinical studies with this agent have shown non-invasive imaging data that is predictive of a cancer patients' response to conventional therapy. This Perspective discusses the evolution of Cu–ATSM, how its selectivity can be improved upon, and where this metal–ligand platform could be taken in the future.

Graphical abstract: Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

Back to tab navigation

Publication details

The article was received on 23 Apr 2007, accepted on 18 Jun 2007 and first published on 25 Sep 2007


Article type: Perspective
DOI: 10.1039/B705989B
Citation: Dalton Trans., 2007,0, 4893-4902
  •   Request permissions

    Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

    A. L. Vāvere and J. S. Lewis, Dalton Trans., 2007, 0, 4893
    DOI: 10.1039/B705989B

Search articles by author

Spotlight

Advertisements